The ionic channel of the nicotinic acetylcholine receptor is unable to differentiate between the optical antipodes of perhydrohistrionicotoxin  by Spivak, C.E. et al.
Volume 163, number 2 l?EBS 0943 November 1983 
The ionic channel of the nicotinic acetylcholine receptor is 
unable to differentiate between the optical antipodes of 
perhydrohistrionicotoxin 
C.E. Spivak+, M.A. Malequet, IL Takahashi’, A. Brossi” and E.X. Albuquerque*+ 
~~~rtrnent of Pharma~olo~ and Experimentai Thera~tics, University of Maryland Medical Schooi, ~aitimore, 
MD 21201, iDepartment of Pharmacology, Meharry Medical College, Nashville, TN 37208 and +Addiction 
Research Center, National Institute of Drug Abuse and National Institute of Arthritis, Diabetes, and Digestive and 
Kidney Diseases, Bethesda, MD 20205, USA 
Received 17 September 1983 
The enantiomers of perhydrohistrionicotoxin were studied in their effects on endplate currents recorded 
at the junctional region of sartorius muscles of Rana pipiens. The two optical antipodes progressively 
decreased the peak amplitude of the endplate currents and were indistinguishable from each other at all 
times. The enantiomers shortened equally the time constants for endplate current decay, but did not alter 
their voltage sensitivities. Although perhydrohistrionicotoxin contains 4 chiral centers, complete steric 
inversion does not alter its effects on the acetylcholine receptor-ion channel complex. By contrast the 
recognition site of the AcChR is extremely sensitive to any change in the chirality of agonists. 
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1. INTRODUCTION 
Among toxins produced by animals, the 
histrionicotoxins have a Spiro linkage and (in the 
unsaturated members) alkyne and allene bonds 
that make them chemically unique f 11. Historically 
these toxins were among the first alkaloids shown 
to block the nicotinic acetylcholine receptor 
(AChR)-ion channel complex by altering the 
kinetics that govern the opening and closing of the 
ionic channel instead of competing for the agonist 
at the recognition site (e.g., [2-g]). These toxins 
cause a voltage-dependent depression of the peak 
amplitudes of endplate currents (EPCs), and they 
shorten the time constants for their decay. Various 
histrionicotoxins have been tested with the intent 
of discerning structure-action relationships [6]. 
All were found to be qualitatively equivalent, 
though their potencies varied. The hypothesis 
+ To whom correspondence should be addressed 
emerged that hydrophobic forces were decisive in 
the actions of these and other non-competitive 
blockers of the AChR (e.g., [6,10]). Recently, the 
enantiomer of the natural ( - )-HIZ-HTX has been 
synthesized [ll]. These toxins possess 4 chiral 
centers (see fig.1) that are attachment points for 
the major functional groups of the molecule. If 
stereoselective binding to the AChR protein exists, 
then one expects different activities for these enan- 
tiomers. On the other hand, if hydrophobic forces 
Fig.1. The structures of natural (- )-Htt-HTX and its 
enantiomer, (+)-HrtHTX. The 4 chiral centers are 
marked with asterisks. 
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predominate, or if the toxins bind to a site with no 
intrinsic asymmetry, one expects no difference in 
activity between enantiomers. The objective of this 
study was to test whether or not the AChR can 
discriminate between these enantiomers of 
HwHTX. 
2. MATERIALS AND METHODS 
The frog Ringer’s solution had the following 
composition (mM): NaCI, 116; KCl, 2.0; CaC12, 
1.8; Na2HP04, 1.3 and NaH2P04, 0.7. The enan- 
tiomers of HIZ-HTX were synthesized by Dr K. 
Takahashi et al. [ll]. Sartorius muscles with the 
sciatic nerve were dissected from the frog Rana pi- 
piens. Both muscles from each frog were always 
used, one for each enantiomer. These matched 
pairs of muscles were used because the toxin 
washes out of muscle so slowly that tests of the two 
enantiomers on the same muscle are impossible. 
To prevent twitch, glycerol shock was used 
[12-141. 
The technique for EPC experiments and analysis 
is described elsewhere [13,14]. It has been shown 
[6] that 10pM Hiz-HTX reduces EPC peak 
amplitude to about 50% of the control value. 
Although higher concentrations deepen the 
blockade and enhance the difference from control 
values, one also finds fibers that are totally block- 
ed or have EPCs too small to be detectable, 
especially at incubation times of 1 h or more. For 
this reason the 10 pM concentration of toxins was 
used for all EPC experiments. 
3. RESULTS 
3.1. Effects of (+I- and (-)-HmHTX on 
parameter of the EPC 
Peak amplitudes of the EPCs were plotted as a 
function of membrane potential (fig.2). The peak 
amplitude at - 150 mV, especially in the presence 
of HwHTX, departs from the linear portion of 
the current-voltage graph. The plot of in 7 vs mem- 
brane potential was linear both in the presence and 
in the absence of the toxins (see also fig.2). The 
logarithms of all peak ~plitudes of the EPC ob- 
tained under control conditions at - 150 mV are 
shown as a histogram in fig.3. A Gaussian curve 
with the same mean, standard deviation and area 
(79 fibers) is superimposed to show that the 
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Fig.2. Two families of EPC peak amplitudes (left) and 
decay time constants (right) obtained under control 
conditions (0) and in the presence of 1OpM ( + )- 
HwHTX (A). These graphs illustrate the means by 
which EPC data were taken as measures of toxin effect. 
These measures were: (1) the slope of the regression line 
(slope conductance) of the current-voltage plot (left) 
calculated for points between + 50 and - 50 mV; (2) the 
EPC peak amplitude at - 150 mV; (3) the linear 
regression parameters for the In r vs mV plot (right) 
evaluated between -50 and - 150 mV. Each curve is 
from a single muscle fiber. 
amplitudes were lognormally distributed. The 
slope conductances also had a lognormal distribu- 
tion (not shown). Therefore, the logarithmic 
transforms of EPC peak amplitudes (at - 150 mV) 
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Fig.3. Histogram of EPC peak amplitudes obtained 
at - 150 mV under control conditions. A Gaussian curve 
with the same mean, standard deviation and area (79 
fibers) is superimposed to show that the amplitudes were 
lognormally distributed. 
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Fig.4. Peak amplitudes of EPCs at - 150 mV under 
control condition (w) and in the presence of (+)- (o), 
and (-)-HIZ-HTX (0) plotted as functions of 
incubation time. Each point represents the (geometric) 
mean of the number of fibers shown; bars represent 
standard errors. 
and slope conductances (in the range +50 and 
- 50 mV, at which peak amplitudes are linear 
functions of membrane potential) were used to 
calculate means and standard errors shown in fig.4 
and 5, respectively. 
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Fig.5. Slope conductances of EPC peak amplitudes 
under control conditions ( n ) and in the presence of (+ )- 
(o), and (-)-Hrz-HTX (0) plotted as functions of 
incubation time. Each point represents the (geometric) 
mean of the number of fibers shown; bars represent 
standard errors. 
As shown in fig.4, the peak EPC amplitudes at 
- 150 mV were progressively blocked by both ( + )- 
and (- )-HIZ-HTX. The blockade developed slow- 
ly and apparently as an exponential function of 
time (the semilog plot is roughly linear) with a half- 
time of around 70 min. By 120 min the EPC peak 
amplitude was about 30% of control. Throughout 
this time, however, the peak amplitudes under 
treatment with ( + )- and ( - )-Hrz-HTX intermin- 
gled, and no statistically significant difference 
could be discerned between them. The slope con- 
ductance (fig.5) also decreased slowly with time 
after adding the toxins. The half-time was some- 
what greater (around 110 min) and the degree of 
blockade at 120 min was less (around 45% of con- 
trol) than the corresponding half-time and blockade 
of peak amplitude at - 150 mV. Again no signifi- 
cant difference between enantiomers could be seen 
at any time. Both enantiomers depressed the time 
constant (7) for decay of the EPC. Slopes of plots 
of In 7 vs membrane potential were unchanged by 
either toxin; the plots were simply shifted down- 
ward while remaining parallel to controls (fig.2). 
The estimated (from the regression line) mpc at 
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Fig.6. Time constants (7) for EPC decays at - 80 mV 
under control conditions ( n ) and in the presence of ( + )- 
(e), or ( -)-HIZ-HTX (0) plotted as a function of 
incubation time. The In T-value for each fiber was 
estimated from linear regression of In 7 on membrane 
potential. At 10,~M (+)- or (-)-Hr2-HTX these plots 
were parallel to control plots, but they were shifted 
downward. The 7 at - 80 is a measure of this downward 
shift. Each point represents the (geometric) mean of the 
number of fibers shown; bars represent standard errors. 
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- 80 mV, taken as a measure of this vertical shift, 
is shown in fig.6 under control conditions and in 
the presence of the enantiomers. The depression in 
nepc progressed until around 60 min, when (in 
contrast to the peak amplitude and slope conduc- 
tance) equably seemed to have been reached. 
At no time, however, could the effects of ( +)- or 
(- )-H~z-HTX be distinguished from one another. 
4. DISCUSSION 
We have shown that the enantiomers of 
Hrz-HTX indistinguishably depressed the peak 
~plitudes and decay time constants of junctional- 
ly recorded EPCs. Dispersion of data was decreas- 
ed by using matched muscles and by pooling data 
according to duration of treatment by Hrz-HTX. 
Although the dispersion that remained could still 
obscure a small difference between the enan- 
tiomers (a ‘type II error’), one can conclude safely 
that stereochemical recognition of a non- 
com~itive antagonist, such as Hrt-HTX, by the 
AChR is far less than it is for an agent that binds 
to the agonist recognition site (see below). In 
agreement with the present results, authors in [15] 
reported no difference between enantiomers of 
pentobarbital in their ability to block carbachol- 
stimulated “Na influx in cultured chick muscle 
cells, On the other hand, the recognition site of the 
AChR can show high stereoselectivity for agonists. 
Thus (+)-anatoxin-a is twice as potent as a 
racemic mixture [16] and the enantiomers of 
trans-3-acetoxy-l-methylthioniacyclohexane differ 
in potency by > 1000: 1 [ 171. Competitive an- 
tagonists also bind stereoselectively, though less 
markedly. For instance, (+)-tubocurarine is 
30-~-times more potent than ( - )-tuboc~arine 
[ 181. Testing a variety of synthetic, competitive an- 
tagonists, potency ratios of about 2: 1 for pairs of 
enantiomers were found in [ 19-221. Higher poten- 
cy ratios could have been found if the compounds 
tested were purely competitive, which is unlikely 
(e.g., HOI). 
Several mechanisms have been proposed to ac- 
count for non-competitive blockade of the AChR 
(e.g., 16,101). Almost certainly several different 
modes and sites of action are involved in the ac- 
tions of various compounds whose observable nd- 
point, the blockade, is the same (e.g., see (10,231). 
A single dissociation constant for ( + )-H~z-HTX at 
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the AChR has been estimated by its effect on the 
time constant of the decay of EPCs to be about 
10/~M [6] and by direct binding assays of the 
tritiated derivative to be about 0. I- 1 pM [7-9,231. 
These constants correspond to a free energy for 
binding of around 7-9 kcab’mol. In a molecule 
such as HQ-HTX, with its two aliphatic side chains 
and its two saturated rings, this energy may easily 
be accounted for by purely hydrophobic factors 
[24] in which binding to the biophase results more 
from the exclusion of the molecule from water 
than from attraction to the biophase. Though 
H;z-HTX contains two polar functional groups 
(NH and OH}, these lie in close pro~mity to one 
another and, in the crystal phase at least, are join- 
ed by an intramolecular hydrogen bond [ 11. They 
may be viewed, therefore, as a single polar center 
on an aliphatic mass. The absence of stereoselec- 
tivity for the H~z-HTX enantiomers at the AChR 
may be due to a functional mirror plane (through 
the molecule) defined by the two polar functional 
groups and a third point such as the Spiro linkage. 
The two flexible, hydrophobic chains can dangle 
on this plane into a hydrophobic region of the 
biophase. The absence of alkyl chains makes the 
remaining molecule a much weaker antagonist 
[25,26]. 
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